EyePoint Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
The Company permits officers and directors to adopt written trading plans, known as “Rule 10b5-1 trading arrangements”, as such term defined in Item 408(a) of Regulation S-K for the purchase or sale of the Company's securities, which are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. During the three months ended March 31, 2024, our executive officers and directors adopted, modified or terminated Rule 10b5-1 trading arrangements for the purchase or sale of our common stock as noted below:
| Name and Title of Director or Officer | Action | Date of Adoption | Duration of the Plan or Termination Date | Aggregate Number of Shares of Common Stock that may be Sold under the Plan |
|---|---|---|---|---|
| Jay Duker, MD, President and Chief Executive Officer | Termination | June 6, 2023 | January 17, 2024 | 146,498 |
| Jay Duker, MD, President and Chief Executive Officer | Adoption | February 7, 2024 | February 7, 2025 | 128,344 |
| Scott Jones, Chief Commercial Officer | Termination | September 21, 2023 | February 6, 2024 | 161,655 |
| Dario Paggiarino, Former Chief Medical Officer | Termination | June 22, 2023 | February 5, 2024 | 204,357 |
| Anthony Adamis,Director | Adoption | February 12, 2024 | February 12, 2025 | 57,766 |
| David Guyer, MD,Director | Adoption | January 25, 2024 | January 31, 2025 | 104,864 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.